Somatic mutations which frequently occur in EGFR tyrosine kinase domain may predict response to EGFR tyrosine kinase inhibitors (TKIs) in patients with non-small cell lung cancer (NSCLC). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.